LivaNova (LIVN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

LivaNova Revenue Highlights

Latest Revenue (Y)

$1.15B

Latest Revenue (Q)

$318.11M

Main Segment (Y)

Cardiopulmonary Segment

Main Geography (Y)

UNITED STATES

LivaNova Revenue by Period

LivaNova Revenue by Year

Date	Revenue	Change
2023-12-31	$1.15B	12.89%
2022-12-31	$1.02B	-1.31%
2021-12-31	$1.04B	10.83%
2020-12-31	$934.20M	-13.84%
2019-12-31	$1.08B	-2.06%
2018-12-31	$1.11B	9.35%
2017-12-31	$1.01B	-16.61%
2016-12-31	$1.21B	316.35%
2015-04-30	$291.56M	3.38%
2014-04-30	$282.01M	10.89%
2013-04-30	$254.32M	16.39%
2012-04-30	$218.50M	14.72%
2011-04-30	$190.46M	13.52%
2010-04-30	$167.78M	16.83%
2009-04-30	$143.60M	18.45%
2008-04-30	$121.23M	-7.44%
2007-04-30	$130.97M	6.10%
2006-04-30	$123.44M	19.33%
2005-04-30	$103.44M	-6.57%
2004-04-30	$110.72M	5.99%
2003-04-30	$104.47M	49.00%
2002-04-30	$70.11M	46.40%
2000-06-30	$47.89M	60.16%
1999-06-30	$29.90M	100.67%
1998-06-30	$14.90M	964.29%
1997-06-30	$1.40M	-
1996-06-30	$1.40M	40.00%
1995-06-30	$1.00M	150.00%
1994-06-30	$400.00K	300.00%
1993-06-30	$100.00K	-

LivaNova generated $1.15B in revenue during NA 2023, up 12.89% compared to the previous quarter, and up 104.20% compared to the same period a year ago.

LivaNova Revenue by Quarter

Date	Revenue	Change
2024-09-30	$318.11M	-0.15%
2024-06-30	$318.57M	8.02%
2024-03-31	$294.91M	-4.90%
2023-12-31	$310.10M	8.39%
2023-09-30	$286.10M	-2.65%
2023-06-30	$293.90M	11.58%
2023-03-31	$263.40M	-4.18%
2022-12-31	$274.90M	8.83%
2022-09-30	$252.60M	-0.63%
2022-06-30	$254.20M	5.84%
2022-03-31	$240.18M	-11.08%
2021-12-31	$270.10M	6.67%
2021-09-30	$253.22M	-4.26%
2021-06-30	$264.48M	6.82%
2021-03-31	$247.60M	-8.16%
2020-12-31	$269.60M	12.29%
2020-09-30	$240.08M	31.76%
2020-06-30	$182.21M	-24.83%
2020-03-31	$242.40M	-15.72%
2019-12-31	$287.60M	7.07%
2019-09-30	$268.61M	-3.09%
2019-06-30	$277.17M	10.51%
2019-03-31	$250.80M	-15.56%
2018-12-31	$297.00M	9.16%
2018-09-30	$272.08M	-5.36%
2018-06-30	$287.50M	14.82%
2018-03-31	$250.40M	-10.06%
2017-12-31	$278.40M	-10.10%
2017-09-30	$309.66M	-3.65%
2017-06-30	$321.39M	12.73%
2017-03-31	$285.11M	-8.21%
2016-12-31	$310.60M	5.19%
2016-09-30	$295.27M	-8.02%
2016-06-30	$321.00M	11.85%
2016-03-31	$287.00M	325.05%
2015-10-18	$67.52M	-16.65%
2015-07-31	$81.01M	9.37%
2015-04-30	$74.07M	2.78%
2015-01-31	$72.07M	-1.84%
2014-10-31	$73.42M	1.96%
2014-07-31	$72.00M	-3.80%
2014-04-30	$74.85M	9.76%
2014-01-31	$68.19M	-2.72%
2013-10-31	$70.10M	1.78%
2013-07-31	$68.87M	0.77%
2013-04-30	$68.34M	9.00%
2013-01-31	$62.70M	-0.41%
2012-10-31	$62.96M	4.37%
2012-07-31	$60.32M	4.71%
2012-04-30	$57.61M	5.63%
2012-01-31	$54.54M	1.57%
2011-10-31	$53.70M	1.96%
2011-07-31	$52.66M	3.01%
2011-04-30	$51.12M	8.58%
2011-01-31	$47.08M	-0.80%
2010-10-31	$47.46M	5.94%
2010-07-31	$44.80M	-6.15%
2010-04-30	$47.73M	16.94%
2010-01-31	$40.82M	0.25%
2009-10-31	$40.72M	5.76%
2009-07-31	$38.50M	-0.20%
2009-04-30	$38.58M	9.41%
2009-01-31	$35.26M	-2.14%
2008-10-31	$36.03M	6.82%
2008-07-31	$33.73M	-0.47%
2008-04-30	$33.89M	7.83%
2007-04-30	$31.43M	-7.93%
2006-10-31	$34.14M	1.21%
2006-07-31	$33.73M	-6.43%
2006-04-30	$36.05M	24.00%
2005-10-31	$29.07M	7.59%
2005-07-31	$27.02M	1.35%
2005-04-30	$26.66M	-

LivaNova generated $318.11M in revenue during Q3 2024, up -0.15% compared to the previous quarter, and up 108.24% compared to the same period a year ago.

LivaNova Revenue Breakdown

LivaNova Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Neuromodulation Segment	$519.71M	$476.99M	$456.17M	$354.44M	$424.55M
Advanced Circulatory Support Segment	$40.32M	$39.30M	$55.46M	-	-
Cardiopulmonary Segment	$588.98M	$500.31M	$482.98M	-	-
Cardiovascular Segment	-	-	-	$577.08M	$656.65M

LivaNova's latest annual revenue breakdown by segment (product or service), as of Dec 23: Cardiopulmonary Segment (51.26%), Neuromodulation Segment (45.23%), and Advanced Circulatory Support Segment (3.51%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19
Neuromodulation Segment	$139.86M	$142.88M	$133.87M	$136.93M	$128.88M	$133.18M	$120.72M	$127.14M	$121.83M	$117.80M	$110.23M	$121.55M	$113.29M	$117.64M	$103.70M	$109.17M	$98.41M	$57.21M	$89.66M	-
Cardiopulmonary Segment	$172.24M	$173.71M	$155.89M	$161.47M	$144.83M	$150.60M	$132.07M	$136.46M	$120.96M	$125.82M	$117.08M	-	-	-	-	-	-	-	-	-
Advanced Circulatory Support Segment	-	-	-	$10.11M	$10.95M	$9.42M	$9.84M	$9.63M	$8.64M	$9.35M	$11.68M	-	-	-	-	-	-	-	-	-
Cardiovascular Segment	-	-	-	-	-	-	-	-	-	-	-	-	$138.63M	$145.88M	$143.17M	$159.60M	$140.88M	$124.53M	$25.21M	-
Cardiac Surgery	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$28.88M
Neuromodulation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$112.54M

LivaNova's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Cardiopulmonary Segment (55.19%), and Neuromodulation Segment (44.81%).

LivaNova Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$635.04M	$571.56M	$571.30M	$468.63M	$546.48M
Europe	$214.79M	$178.80M	$201.53M	$193.37M	$223.18M
Locations Excluding The United States And Europe	$303.71M	$271.44M	$262.54M	$272.24M	-
Rest Of World	-	-	-	-	$314.50M

LivaNova's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (55.05%), Locations Excluding The United States And Europe (26.33%), and Europe (18.62%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19
UNITED STATES	$179.83M	$179.54M	$160.62M	$173.22M	$161.58M	$159.97M	$140.27M	$153.79M	$143.41M	$138.09M	$136.27M	$149.83M	$40.14M	$2.21M	$2.72M	$138.00M	$3.13M	$2.49M	-	-
Locations Excluding The United States And Europe	$85.48M	$87.78M	$79.95M	$74.35M	$76.40M	$79.45M	$73.51M	$74.78M	$69.20M	$68.69M	$58.78M	$71.29M	$50.24M	$6.39M	$10.45M	$76.79M	$10.06M	$9.63M	$671.00K	-
Europe	$52.81M	$51.26M	$54.34M	$62.56M	$48.13M	$54.46M	$49.64M	$46.31M	$40.00M	$47.37M	$45.13M	$48.95M	$32.85M	$6.12M	$8.28M	$54.76M	$7.95M	$5.35M	-	-
Rest Of World	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$641.00K

LivaNova's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (56.53%), Locations Excluding The United States And Europe (26.87%), and Europe (16.60%).

LivaNova Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BRKR	Bruker	$2.96B	$800.70M
ITGR	Integer	$1.60B	$746.27M
GMED	Globus Medical	$1.57B	$625.71M
CNMD	CONMED	$1.24B	$316.70M
LIVN	LivaNova	$1.15B	$318.11M
IRTC	iRhythm	$492.68M	$147.54M
ATEC	Alphatec	$482.26M	$47.99M
GKOS	Glaukos	$314.71M	$96.67M
FNA	Paragon 28	$216.39M	$61.02M
KIDS	OrthoPediatrics	$148.73M	$52.80M
SIBN	SI-BONE	$138.89M	$40.34M
LUNG	Pulmonx	$68.67M	$20.39M
NPCE	NeuroPace	$65.42M	$21.06M
OFIX	Orthofix Medical	$100.00K	$198.62M

LIVN Revenue FAQ

What is LivaNova’s yearly revenue?

LivaNova's yearly revenue for 2023 was $1.15B, representing an increase of 12.89% compared to 2022. The company's yearly revenue for 2022 was $1.02B, representing a decrease of -1.31% compared to 2021. LIVN's yearly revenue for 2021 was $1.04B, representing an increase of 10.83% compared to 2020.

What is LivaNova’s quarterly revenue?

LivaNova's quarterly revenue for Q3 2024 was $318.11M, a -0.15% decrease from the previous quarter (Q2 2024), and a 11.19% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $318.58M, a 8.02% increase from the previous quarter (Q1 2024), and a 8.40% increase year-over-year (Q2 2023). LIVN's quarterly revenue for Q1 2024 was $294.91M, a -4.90% decrease from the previous quarter (Q4 2023), and a 11.96% increase year-over-year (Q1 2023).

What is LivaNova’s revenue growth rate?

LivaNova's revenue growth rate for the last 3 years (2021-2023) was 11.41%, and for the last 5 years (2019-2023) was 6.39%.

What are LivaNova’s revenue streams?

LivaNova's revenue streams in c 23 are Neuromodulation Segment, Advanced Circulatory Support Segment, and Cardiopulmonary Segment. Neuromodulation Segment generated $519.71M in revenue, accounting 45.23% of the company's total revenue, up 8.96% year-over-year. Advanced Circulatory Support Segment generated $40.32M in revenue, accounting 3.51% of the company's total revenue, up 2.60% year-over-year. Cardiopulmonary Segment generated $588.98M in revenue, accounting 51.26% of the company's total revenue, up 17.72% year-over-year.

What is LivaNova’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of LivaNova was Cardiopulmonary Segment. This segment made a revenue of $588.98M, representing 51.26% of the company's total revenue.